Review Article

Telomere Length Reprogramming in Embryos and Stem Cells

Keri Kalmbach,1 LeRoy G. Robinson Jr.,1 Fang Wang,1 Lin Liu,1,2 and David Keefe1

1 Department of Obstetrics and Gynecology, New York University Langone Medical Center, 180 Varick Street, No. 761, New York, NY 10014, USA
2 College of Life Sciences, Nankai University, Tianjin 300071, China

Correspondence should be addressed to Keri Kalmbach; keri.kalmbach@nyumc.org

Received 9 November 2013; Accepted 15 January 2014; Published 27 February 2014

Academic Editor: Xu-Dong Zhu

Copyright © 2014 Keri Kalmbach et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Telomeres protect and cap linear chromosome ends, yet these genomic buffers erode over an organism’s lifespan. Short telomeres have been associated with many age-related conditions in humans, and genetic mutations resulting in short telomeres in humans manifest as syndromes of precocious aging. In women, telomere length limits a fertilized egg’s capacity to develop into a healthy embryo. Thus, telomere length must be reset with each subsequent generation. Although telomerase is purportedly responsible for restoring telomere DNA, recent studies have elucidated the role of alternative telomeres lengthening mechanisms in the reprogramming of early embryos and stem cells, which we review here.

1. Introduction

Telomeres are tandem DNA repeats (TTAGGG)n which provide the substrate for specialized proteins to bind and loop chromosome ends. Telomeres prevent chromosome end-joining and ward off DNA damage repair machinery that would otherwise inappropriately repair the telomere as a double-stranded DNA break.

In humans, most tissues exhibit a marked decrease in telomere reserve over time [1, 2]. Cell division, oxidative damage, and genotoxic insults can directly or by way of DNA damage repair responses reduce the amount of DNA capping the chromosome end. Excessive telomere shortening induces cell senescence and eventually apoptosis [3]. Telomere DNA can be replenished by telomerase [3–5], a reverse-transcriptase-acting holoenzyme that adds a modest 50–100 bp per round of cell division. Expression of telomerase in humans is limited to highly proliferative tissues which harbor progenitor or stem cell compartments. In contrast to humans, many model organisms such as outbred mouse strains have constitutive telomerase expression coincident with longer telomeres. Recombination-mediated alternative lengthening of telomeres (ALT) pathway(s) have been proposed [6–8], which can augment telomere length by thousands of base-pairs within a few cell cycles [9].

Telomere biology is an emerging field that holds great promise for advancing clinical medicine, particularly for aging and age-related diseases. Short telomeres have been associated with the gamut of age-related diseases, including diabetes mellitus [10, 11], cardiovascular disease [12], liver disorders [13, 14], cancer [15–19], and death from all causes [20]. Moreover, long telomeres have been associated with exceptional longevity and increased lifespan [21]. Chemical or genetic depletion of telomere length recapitulates many of these pathologies in mouse models.

Direct evidence for the importance of telomere length in human disease derives from patients with mutations in TERT and TERC, the genes encoding the reverse transcriptase and RNA component of telomerase, respectively. Dyskeratosis Congenita, the prototypical telomere syndrome, results from mutations in the gene encoding many of the telomere maintenance genes, including TERT, TERC, TINF2, and DKC [16, 22–27]. This disorder manifests in tissues prone to high turnover, such as liver, fingernail beds, mucous membranes, and the hematopoietic system [16]. Symptoms arise when telomere lengths become critically short, which limits the ability of progenitor cells to maintain the differentiated cell populations in these tissues, leading to eventual organ system failure. Further, patients have a higher risk of developing...
cancer [28], particularly in those organs susceptible to telomere attrition. In families with inherited germline mutations in TERC and TERT, telomere length across generations is inversely related to the severity of disease manifestations. This genetic anticipation has also been documented in hereditary cancers [15].

Cellular reprogramming, resetting the aging process, requires purging of aged maternal proteins, degradation of maternal transcripts, resetting methylation cues, and rejuvenation of the genome and other cellular components. One paradigm to model this is somatic cell nuclear transfer (SCNT), where an adult cell is transplanted into an enucleated oocyte. Interestingly, though Dolly the Sheep, the first mammal cloned by SCNT, exhibited signs of precocious aging, presumably due to incompletely reset telomeres inherited from the donor somatic cell. Here, we will review in vivo and in vitro data on telomere length reprogramming, with particular emphasis on systems with the greatest promise for the future of personalized medicine.

2. Telomere Lengthening in Embryos

Mammalian oocytes arrest following the extrusion of the first polar body and prior to completion of meiosis II. Fertilization by a competent sperm leads to the extrusion of the second polar body, rendering the oocyte haploid to complement the incoming paternal genome. What is known about telomere dynamics during this period is largely limited to observational studies, both in mouse and human.

Telomere length in the oocyte is markedly shorter than somatic cells [9, 29–31], which is particularly intriguing given that the majority of an oocyte’s lifespan is spent in meiosis, when replication-linked telomere attrition is thought not to have an influence. High reactive oxygen species, generalized aging, and lack of telomerase activity conspire to reduce telomere length in oocytes [30, 32, 33]. In contrast, sperm are of the few cell types documented to elongate telomeres over the human lifespan [34–37], presumably due to the effects of telomerase activity in spermatogonia throughout the life of the male.

Following fertilization and activation of the egg, embryonic cells undergo dramatic telomere lengthening [9, 31, 38, 39]. In mouse, telomere length increases by thousands of base-pairs within the first one or two cell cycles [9], nearly doubling from the baseline oocyte length to the two-cell stage. Notably, telomerase activity remains undetectable in these cells. Instead, embryos exhibit high rates of telomere sister chromatid exchange (T-SCE), telomere-specific localization of recombination proteins, and a favorable chromatin state. This effect remains robust in telomerase knock-out mice, suggesting an ALT-dependent mechanism at play in preimplantation mammalian development. Moreover, the lengthening takes place in parthenogenetically activated eggs, which lack sperm input during activation, suggesting that the capacity for telomere length reprogramming resides in the oocyte.

Whereas telomerase-independent, recombination-based telomere elongation takes place during early preimplantation development, telomerase activity increases dramatically at the blastocyst stage of development (see Figure 1). The greatest degree of telomere lengthening occurs in the inner cell mass, the pluripotent cells giving rise to the embryo proper [40], in contrast to the trophectoderm, which gives rise to tissues that will become placenta and other extra embryonic tissues. Interestingly, telomere length in the inner cell mass is substantially shorter than that of embryonic stem cells, which lengthen after several passages in culture. Studies of telomere length dynamics during early embryo development and blastocyst development and during formation of ESCs should be conducted on human tissue.

Owing to the limitations in the United States for using human embryos in research, these studies have not been directly repeated in humans. However, one group based in the United Kingdom attempted to resolve telomere length at the level of the individual chromosome by utilizing semiquantitative fluorescent in situ hybridization (QFISH) with individual gametes and pronuclear embryos [41, 42]. This group found that telomere length is shorter in sperm than oocytes, including in immature oocytes and mature oocytes and at the pronuclear stage. The results of these experiments are open to interpretation for several reasons. Until fertilization, immature and mature oocytes contain twice the amount of DNA as sperm. Moreover, QFISH usually requires metaphase spreads to measure telomere length, so the use of individual interphase spreads needs to be validated. Sperm and oocyte telomere length discrepancies found by this method could also be accounted for by differing chromatin states that allow the probe to have more ready access to the oocyte pronucleus over the highly condensed male pronucleus. Methods which account for DNA copy number, such as single cell qPCR [31], could correct for these shortcomings.

Assisted reproductive technologies afford the opportunity to directly access human gametes and embryos, allowing for such studies of telomere length dynamics during human preimplantation development. Such studies have revealed shorter telomeres in oocytes of women who do not conceive following IVF compared to those who do [29] and in oocytes from cycles producing fragmented embryos [43]. Moreover, shorter telomere length was found in aneuploid blastomeres and polar bodies than in euploid cells from the same IVF patient and cycle [39], which is consistent with similar findings in mouse models with short telomeres [44]. Indeed, a wide range of complications of advanced reproductive age have been associated with shorter telomere length, including Down syndrome [45] and recurrent miscarriage [46] (also reviewed in [30]).

Although the studies provide a unique insight into events during telomere reprogramming, these studies by necessity remain observational. Interestingly, a variety of studies have revealed basic reprogramming capacity in offspring from somatic cell nuclear transfer (SCNT), which creates a cloned embryo, such as Dolly the Sheep. Since the telomeres in somatic cells in most mammalian species exhibit age-related decline, use of SCNT-cloned animals provides an interesting sample of reprogramming across species. Newborn clones of pig and cattle exhibit normal telomere lengthening during embryonic reprogramming, although the rate of production of viable, full-term offspring by way of SCNT is very low
Figure 1: Schematic of telomere length reprogramming in mammalian embryonic development. The greatest telomere lengthening takes place during the earliest stages of preimplantation development, the cleavage-stage embryo, which may coincide with zygote genome activation. Recombination-mediated telomere lengthening (ALT) is also purportedly responsible for reprogramming in pluripotent stem cells, including ESCs, ntESCs, and iPSCs. Later, in development and adult life, telomerase becomes the dominant telomere maintenance mechanism for the inner cell mass and in tissue-specific telomere replenishment in stem cell niches.

[47–51]. Minor discrepancies in the degree of telomere lengthening amongst these studies might be explained by the small sample sizes and the differential time points of tissue selection for telomere length analysis. Overall, these studies are consistent with observational studies in human and experimental studies in mouse that demonstrated a minimum telomere length is likely required for the development of a competent embryo; to determine this experimentally, it would be intriguing to increase telomere length and examine efficiency of SCNT and production of cloned embryos.

3. Telomere Length Reprogramming in Stem Cells

Stem cells are defined not only by their differentiation potential but also by their capacity for unlimited self-replication. The need for prolonged self-replication requires adequate telomere length and telomere maintenance, which can limit the powerful new methods available for generating induced pluripotent cells. iPSCs lacking sufficient telomere length fail to achieve germline transmission or tetraploid complementation, the most stringent tests of pluripotency, and cannot be maintained in culture over long periods. This might have contributed, in part, to the variable quality of iPSCs during early efforts by the Yamanaka group and the initial failure of these cells to contribute to chimeras and may ultimately limit the future application of iPSCs in regenerative medicine [52, 53]. To correct this, present efforts in the field of iPSCs have strived to improve the quality of iPSC generated by focusing on telomere dynamics during the process of reprogramming.

Late passage, telomerase-deficient (\(T_{erc}^{-/-}\)) murine embryonic stem cells (ESC) possessing critically short telomeres show reduced cell growth, reduced ability to form teratomas, and failure to transmit through the germline to form chimeras [54]. Since expression of the common pluripotency markers (Oct4, Nanog, Sox2, Lin28, etc.) does not differ between telomerase-deficient and wild type ESCs, telomere length may provide a more sensitive measure of pluripotency. Further work generated telomerase haploinsufficient and deficient (\(T_{erc}^{-/-}\) and \(T_{erc}^{-/-}\)) iPSCs, revealing telomerase dispensability during the reprogramming process while also demonstrating the requirement for telomerase to maintain telomeres and pluripotency in iPSC during culture [55]. Identifying lack of true pluripotency in iPSC with short telomeres recapitulated earlier suggestions linking telomere length with detection of pluripotent status. This study also revealed an increased rate of telomere sister chromatid exchange (T-SCE) in the absence of full telomerase function, demonstrating a telomerase-independent mechanism (ALT) at work during reprogramming. In particular, this study implicated limited telomerase function (possibly arising from poor activation by pluripotency factors) and reactivation of exogenous pluripotency factors in response to loss of full telomerase function, in addition to ALT in contributing to telomere length variability in iPSC reprogramming.

Recombination events such as T-SCE require reductions in DNA methylation and epigenetic remodeling and are frequently associated with genomic stability [56]. Understanding the epigenetic mechanisms regulating telomere length is critical for improving the quality of iPSC. Critically short telomeres in a telomerase-deficient (\(T_{erc}^{-/-}\)) ESC model exhibited reduced global hypomethylation and altered levels of H3k27me3, which led to increased Nanog and Gata 6 expression, inducing reversible differentiation [57]. Rescue of stable differentiation was achieved by restoration of Dnmt3b or inhibition of Nanog resulting in reversed global DNA hypomethylation and normal repression of Nanog by de novo methylation. This work led to a model in which adequate telomere length directly impacts the ability of cells to maintain stable differentiation capacity.

\(Z_{scan4}\) is emerging as a potentially important factor in generating high-quality iPSCs. First identified for its essential
role in development from 2-cell to 4-cell embryos [58], Zscan4 was later shown to play a role in ESC regulation. Importantly, a Zscan4-positive state has been observed in ESC populations, where it colocalizes to telomeres and accompanies telomere elongation [59]. Moreover, Zscan4 knockdown accompanied reduced proliferation, decreased T-SCE, decreased telomere length, and abnormal karyotype. Over subsequent passages, the majority of Zscan4-deficient cells became cell cycle arrested. Taken together, these findings point to an essential role for Zscan4 in regulation of telomere length in order to perhaps protect cells from genomic instability. Interestingly, the addition of Zscan4 to Yamanaka factor reprogramming produced tetraploid-complementation competent cells with longer telomeres than traditional iPSC, enabling the formation of chimeras from over 50% of cell lines generated. More recent work has elucidated the regulatory relationship between Tbx3 and Zscan4, namely, that Tbx3 can activate Zscan4 by inhibiting DNA methylation at subtelomeric regions, leading to depression of genes in this region (e.g., Zscan4) [60]. The addition of Zscan4 or Tbx3 to the reprogramming protocol resulted in iPSC able to pass the most stringent tests of pluripotency and pushes closer toward the development of a protocol for iPSC suitable for clinical application [61].

In humans, the nature of telomere reprogramming has recapitulated many findings in other model organisms. Generation of human iPSC (hiPSC) from patient cells with the telomere disorder Dyskeratosis Congenita demonstrated the ability to elongate telomeres after reprogramming [62]. While in early passages these dyskerin-mutated (DKC1) hiPSC lines showed gradual telomere reduction, prolonged culture enabled telomere resetting to match the length of parent fibroblasts, indicating that the TERC deficiency within these cells had been overcome by the reprogramming process. Other work with DKC1 hiPSC revealed that extended culture led to telomere shortening and spontaneous differentiation [63]. Additionally, iPSC from patients with mutations in telomerase itself (TCAB1) that cause mislocalization of the enzyme fail to lengthen telomeres despite having normal telomerase activity, indicating that proper localization is as critical a factor as activity for telomere maintenance. Combined, these data reinforce that many factors affecting telomere length and telomere maintenance ultimately impact pluripotency and self-renewal of human and animal cells.

SCNT would provide the gold standard for production of personalized stem cells for humans, as the resulting progeny are veritable clones of the donor genome. Although methods for deriving SCNT stem cells were conceived over a decade ago, this was only successfully completed in humans very recently due to excessive technical difficulty and ethical limitations [64]. Recently, a direct comparative study between SCNT derived cells (ntESC) and iPSC from telomerase-deficient (Terc−/−) mice has explicitly determined that SCNT significantly increases telomere lengthening during reprogramming and improves differentiation capacity and proliferative ability relative to Yamanaka reprogramming. The data suggest that SCNT produces superior pluripotent cells and that the process can rescue differentiation ability in cells with critically short telomeres. Still, the requirement for high-quality human oocytes for SCNT will likely drive more in-depth studies into the factors within the oocyte necessary to produce superior stem cells [65]. These factors, once isolated, will likely have an explosive impact on Yamanaka reprogramming both in terms of the quality of the cells and the efficiency of the process.

4. Discussion

Advances in modern medicine have led to remarkable prolongation of human life span. Concomitantly, an increase in delayed child rearing until later in life has led to reduced fecundity. As a result, the burden of age-related diseases and infertility makes elucidation of the pathobiology of aging an urgent priority.

iPSCs bypass the ethical and immune-compatibility issues that limit application of embryonic stem cells for therapeutic purposes. Not only do these iPSCs promise to provide advanced models and treatments of complex human diseases, but the efficiency of reprogramming, especially pertaining to telomeres, must be fully addressed before clinical applications can be considered.

In human reproduction, a minimum telomere length is likely required for production of a competent embryo, as in the development of pluripotent cell lines. Lessons from reproduction, such as the discovery of the ZScan4 factor, may help increase the efficiency of reprogramming methods and the clinical practicality of the resulting cells. In particular, members of the shelterin complex have been shown to be critical for reprogramming efficiency [66, 67]. For instance, while TRFI expression level cannot be correlated with telomere length, the presence of TRFI is essential for induction and maintenance of pluripotency in iPSC, in addition to significant correlations between the level TRFI and the level of potency in the resulting cells. Moreover, epigenetic states of the subtelomere seem to positively regulate telomere lengthening through recombination [68–70] and may someday improve reprogramming efficiency. Expanding our knowledge of the basic biology telomeres may hold the key to correcting age-related infertility and other age-related diseases.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Keri Kalmbach and LeRoy G. Robinson Jr. contributed equally to this work.

Acknowledgments

Funding is provided by the NYU Department of Obstetrics and Gynecology and the Clinical and Translational Sciences Institute at NYU (NIH: no.1UL1RR029893).
References

[1] U. Friedrich, E. U. Griese, M. Schwab, P. Fritz, K. P. Thon, and U. Klotz, “Telomere length in different tissues of elderly patients,” *Mechanisms of Ageing and Development*, vol. 119, no. 3, pp. 89–99, 2000.

[2] C. B. Harley, A. B. Futcher, and C. W. Greider, “Telomeres shorten during ageing of human fibroblasts,” *Nature*, vol. 345, no. 6274, pp. 458–460, 1990.

[3] T. de Lange, “How telomeres solve the end-protection problem,” *Science*, vol. 326, no. 5955, pp. 948–952, 2009.

[4] T. R. Cech, “Beginning to understand the end of the chromosome,” *Cell*, vol. 116, no. 2, pp. 273–279, 2004.

[5] C. W. Greider and E. H. Blackburn, “Identification of a specific telomere terminal transferase activity in tetrahymena extracts,” *Cell*, vol. 43, no. 2, pp. 405–413, 1985.

[6] M. A. Dunham, A. A. Neumann, C. L. Fasching, and R. R. Reddel, “Telomere maintenance by recombination in human cells,” *Nature Genetics*, vol. 26, no. 4, pp. 447–450, 2000.

[7] J. Henson, A. Neumann, T. Yeager, and R. Reddel, “Alternative lengthening of telomeres in mammalian cells,” *Oncogene*, vol. 21, no. 4, pp. 598–610, 2002.

[8] A. A. Neumann, C. M. Watson, J. R. Noble et al., “Alternative lengthening of telomeres in normal mammalian somatic cells,” *Genes and Development*, vol. 27, no. 1, pp. 18–23, 2013.

[9] L. Liu, S. M. Bailey, M. Okuka et al., “Telomere lengthening early in development,” *Nature Cell Biology*, vol. 9, no. 12, pp. 1436–1441, 2007.

[10] B. Murillo-Ortiz, F. Albarrán-Tamayo, D. Arenas-Aranda et al., “Telomere length and type 2 diabetes in males, a premature aging syndrome,” *Aging Male*, vol. 15, no. 1, pp. 54–58, 2012.

[11] M. Du, J. Prescott, M. C. Cornelis et al., “Genetic predisposition to higher body mass index or type 2 diabetes and leukocyte telomere length in the Nurses’ Health Study,” *PLoS ONE*, vol. 8, no. 2, Article ID e52240, 2013.

[12] A. L. Fitzpatrick, R. A. Kronmal, M. Kimura et al., “Leukocyte telomere length and mortality in the Cardiovascular Health Study,” *The Journals of Gerontology A*, vol. 66, no. 4, pp. 421–429, 2011.

[13] D. Hartmann, U. Srivastava, M. Thaler et al., “Telomerase gene mutations are associated with cirrhosis formation,” *Hepatology*, vol. 53, no. 5, pp. 1608–1617, 2011.

[14] R. T. Calado, J. Brudno, P. Mehta et al., “Constitutional telomere mutations are genetic risk factors for cirrhosis,” *Hepatology*, vol. 53, no. 5, pp. 1600–1607, 2011.

[15] B. Martinez-Delgado, K. Yanovsky, L. Ingla-Perez et al., “Genetic anticipation is associated with Telomere shortening in hereditary breast cancer,” *PLoS Genetics*, vol. 7, no. 7, Article ID e1002182, 2011.

[16] M. Armanios, “Telomeres and age-related disease: how telomere biology informs clinical paradigms,” *The Journal of Clinical Investigation*, vol. 123, no. 3, pp. 996–1002, 2013.

[17] C. Gunes and K. L. Rudolph, “The role of telomeres in stem cells and cancer,” *Cell*, vol. 152, no. 3, pp. 390–393, 2013.

[18] C. M. Heaphy, G. S. Yoon, S. B. Peskoe et al., “Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death,” *Cancer Discovery*, vol. 3, no. 10, pp. 1130–1141, 2013.

[19] E. Kuhn, A. K. Meeker, K. Visvanathan et al., “Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma,” *Modern Pathology*, vol. 24, no. 8, pp. 1139–1145, 2011.

[20] W. Chen, M. Kimura, S. Kim et al., “Longitudinal versus cross-sectional evaluations of leukocyte telomere length dynamics: age-dependent telomere shortening is the rule,” *Journals of Gerontology A*, vol. 66, no. 3, pp. 312–319, 2011.

[21] G. Atzmon, M. Cho, R. M. Cawthon et al., “Evolution in health and medicine Sackler colloquium: genetic variation in human telomerase is associated with telomere length in Ashkenazi centenarians,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, 1, pp. 1710–1717, 2010.

[22] B. R. Houghtaling, S. Canudas, and S. Smith, “A role for sister telomere cohesion in telomere elongation by telomerase,” *Cell Cycle*, vol. 11, no. 1, pp. 19–25, 2012.

[23] S. A. Savage, N. Giri, G. M. Baelocher, N. Orr, P. M. Lansdorp, and B. P. Alter, “TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita,” *The American Journal of Human Genetics*, vol. 82, no. 2, pp. 501–509, 2008.

[24] S. A. Savage and A. A. Bertuch, “The genetics and clinical manifestations of telomere biology disorders,” *Genetics in Medicine*, vol. 12, no. 12, pp. 753–764, 2010.

[25] T. Vulliamy, A. Marrone, F. Goldman et al., “The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita,” *Nature*, vol. 413, pp. 432–435, 2001.

[26] S. Knight, T. Vulliamy, A. Coppolestone, E. Gluckman, P. Mason, and I. Dokal, “Dyskeratosis congenita (DC) registry: identification of new features of DC,” *British Journal of Haematology*, vol. 103, no. 4, pp. 990–996, 1998.

[27] N. S. Heiss, S. W. Knight, T. J. Vulliamy et al., “X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions,” *Nature Genetics*, vol. 19, no. 1, pp. 32–38, 1998.

[28] B. P. Alter, N. Giri, S. A. Savage, and P. S. Rosenberg, “Cancer in dyskeratosis congenita,” *Blood*, vol. 113, no. 6, pp. 6549–6557, 2009.

[29] D. L. Keefe, L. Liu, and K. Marquard, “Telomeres and aging-related meiotic dysfunction in women,” *Cellular and Molecular Life Sciences*, vol. 64, no. 2, pp. 139–143, 2007.

[30] K. H. Kalmbach, D. M. F. Antunes, R. C. Draxler et al., “Telomeres and Human Reproduction,” *Fertility and Sterility*, vol. 99, no. 1, pp. 23–29, 2013.

[31] F. Wang, X. Pan, K. Kalmbach et al., “Robust measurement of telomere length in single cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 21, pp. E1906–E1912, 2013.

[32] T. Yamada-Fukunaga, M. Yamada, T. Hamatani et al., “Age-associated telomere shortening in mouse oocytes,” *Blood*, vol. 113, no. 26, pp. 6549–6557, 2009.

[33] M. Liu, Y. Yin, X. Ye et al., “Resveratrol protects against age-associated infertility in mice,” *Human Reproduction*, vol. 28, no. 3, pp. 707–717, 2013.

[34] A. Gibbons, “Older dads have healthier kids than you think,” *Science*, vol. 336, no. 6081, p. 539, 2012.

[35] D. T. Eisenberg, M. G. Hayes, and C. W. Kuzawa, “Delayed paternal age of reproduction in humans is associated with longer telomeres across two generations of descendants,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 109, no. 26, pp. 10251–10256, 2012.

[36] M. Kimura, L. F. Cherkas, B. S. Kato et al., “Offspring’s leukocyte telomere length, paternal age, and telomere elongation in sperm,” *PLoS Genetics*, vol. 4, no. 2, article e37, 2008.
[37] J. Prescott, M. Du, J. Y. Wong, J. Han, and I. de Vivo, “Paternal age at birth is associated with offspring leukocyte telomere length in the nurses’ health study,” *Human Reproduction*, vol. 27, no. 12, pp. 3622–3631, 2012.

[38] S. Schaetzlein, A. Lucas-Hahn, E. Lemme et al., “Telomere length is reset during early mammalian embryogenesis,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 21, pp. 8034–8038, 2004.

[39] N. R. Treff, J. Su, D. Taylor, and R. T. Scott, “Telomere dna deficiency is associated with development of human embryonic aneuploidy,” *PLoS Genetics*, vol. 7, no. 6, Article ID e1002161, 2011.

[40] E. Varela, R. P. Schneider, S. Ortega, and M. A. Blasco, “Different telomere-length dynamics at the inner cell mass versus established embryonic stem (ES) cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 37, pp. 15207–15212, 2011.

[41] S. Turner, H. P. Wong, J. Rai, and G. M. Hartshorne, “Telomere lengths in human oocytes, cleavage stage embryos and blastocysts,” *Molecular Human Reproduction*, vol. 16, no. 9, pp. 685–694, 2010.

[42] S. Turner and G. M. Hartshorne, “Telomere lengths in human pronuclei, oocytes and spermatozoa,” *Molecular Human Reproduction*, vol. 19, no. 8, pp. 510–518, 2013.

[43] D. L. Keefe, S. Franco, L. Liu et al., “Telomere length predicts embryo fragmentation after in vitro fertilization in women—toward a telomere theory of reproductive aging in women,” *The American Journal of Obstetrics and Gynecology*, vol. 192, no. 4, pp. 1256–1261, 2005.

[44] L. Liu, M. A. Blasco, J. R. Trimarchi, and D. L. Keefe, “An essential role for functional telomeres in mouse germ cells during fertilization and early development,” *Developmental Biology*, vol. 249, no. 1, pp. 74–84, 2002.

[45] S. Ghosh, E. Feingold, S. Chakraborty, and S. K. Dey, “Telomere length is associated with types of chromosome 21 nondisjunction: a new insight into the maternal age effect on down syndrome birth,” *Human Genetics*, vol. 127, no. 4, pp. 403–409, 2010.

[46] C. W. Hanna, K. L. Bretherick, J. L. Gair et al., “Telomere length and reproductive aging,” *Human Reproduction*, vol. 24, no. 5, pp. 1206–1211, 2009.

[47] H. Y. Jeon, S. H. Hyun, G. S. Lee et al., “The analysis of telomere length and telomerase activity in cloned pigs and cows,” *Molecular Reproduction and Development*, vol. 71, no. 3, pp. 315–320, 2005.

[48] N. Miyashita, Y. Kubo, M. Yonai et al., “Cloned cows with short telomeres deliver healthy offspring with normal-length telomeres,” *Journal of Reproduction and Development*, vol. 57, no. 5, pp. 636–642, 2011.

[49] S. Imsoonthornruksa, A. Sangmalee, K. Srirattana, R. Pornpim, and M. Ketudat-Cairns, “Development of intergeneric and intrageneric somatic cell nuclear transfer (SCNT) cat embryos and the determination of telomere length in cloned offspring,” *Cellular Reprogramming*, vol. 14, no. 1, pp. 79–87, 2012.

[50] D. H. Betts, V. Bordignon, J. R. Hill et al., “Reprogramming of telomerase activity and rebuilding of telomere length in cloned cattle,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 3, pp. 1077–1082, 2001.

[51] G. F. Mastromonaco, S. D. Perrault, D. H. Betts, and W. A. King, “Role of chromosome stability and telomere length in the production of viable cell lines for somatic cell nuclear transfer,” *BMC Developmental Biology*, vol. 6, no. 4, 2006.

[52] K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” *Cell*, vol. 131, no. 5, pp. 861–872, 2007.

[53] K. Takahashi and S. Yamanaka, “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,” *Cell*, vol. 126, no. 4, pp. 663–676, 2006.

[54] J. Huang, F. Wang, M. Okuka et al., “Association of telomere length with authentic pluripotency of ES/iPS cells,” *Cell Research*, vol. 21, no. 5, pp. 779–792, 2011.

[55] F. Wang, Y. Yin, X. Ye et al., “Molecular insights into the heterogeneity of telomere reprogramming in induced pluripotent stem cells,” *Cell Research*, vol. 22, no. 4, pp. 757–768, 2012.

[56] M. A. Blasco, “The epigenetic regulation of mammalian telomeres,” *Nature Reviews Genetics*, vol. 8, no. 4, pp. 299–309, 2007.

[57] F. Pucci, L. Gardano, and L. Harrington, “Short telomeres in ESCs lead to unstable differentiation,” *Cell Stem Cell*, vol. 12, no. 4, pp. 479–486, 2013.

[58] G. Falco, S. L. Lee, I. Stanghellini, U. C. Bassey, T. Hamatani, and M. S. H. Ko, “Zscan4: a novel gene expressed exclusively in late 2-cell embryos and embryonic stem cells,” *Developmental Biology*, vol. 307, no. 2, pp. 539–550, 2007.

[59] M. Zalzman, G. Falco, L. V. Sharova et al., “Zscan4 regulates telomere elongation and genomic stability in ES cells,” *Nature*, vol. 464, no. 7290, pp. 858–863, 2010.

[60] J. Dan, M. Li, and J. Yang, “Roles for Tbx3 in regulation of two-cell stage and telomere elongation in mouse ES cells,” *Scientific Reports*, vol. 3, article 3492, 2013.

[61] J. Jiang, W. Lv, X. Ye et al., “Zscan4 promotes genomic stability during reprogramming and dramatically improves the quality of iPS cells as demonstrated by tetraploid complementation,” *Cell Research*, vol. 23, no. 1, pp. 92–106, 2013.

[62] S. Agarwal, Y. H. Loh, E. M. McLoughlin et al., “Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients,” *Nature*, vol. 464, no. 7286, pp. 292–296, 2010.

[63] L. F. Z. Batista, M. F. Pech, F. L. Zhong et al., “Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells,” *Nature*, vol. 474, no. 7351, pp. 399–404, 2011.

[64] M. Tachibana, P. Amato, M. Sparman et al., “Human embryonic stem cells derived by somatic cell nuclear transfer,” *Cell*, vol. 153, no. 6, pp. 1228–1238, 2013.

[65] R. Le, Z. Kou, Y. Jiang et al., “Enhanced telomere rejuvenation in pluripotent cells reprogrammed via nuclear transfer relative to induced pluripotent stem cells,” *Cell Stem Cell*, vol. 14, no. 1, 2013.

[66] S. Yehezkel, A. Rebibo-Sabbah, Y. Segev et al., “Suv4-20h deficiency results in telomere elongation and derepression of telomere recombination,” *Journal of Cell Biology*, vol. 178, no. 6, pp. 925–936, 2007.
[69] R. Benetti, M. Garcia-Cao, and M. A. Blasco, “Telomere length regulates the epigenetic status of mammalian telomeres and subtelomeres,” *Nature Genetics*, vol. 39, no. 2, pp. 243–250, 2007.

[70] S. Gonzalo, I. Jaco, M. F. Fraga et al., “DNA methyltransferases control telomere length and telomere recombination in mammalian cells,” *Nature Cell Biology*, vol. 8, no. 4, pp. 416–424, 2006.